<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941379</url>
  </required_header>
  <id_info>
    <org_study_id>Registry AU-011-401</org_study_id>
    <nct_id>NCT03941379</nct_id>
  </id_info>
  <brief_title>A Registry of Patients With Primary Indeterminate Lesions or Choroidal Melanoma</brief_title>
  <official_title>A Registry of Patients With Primary Indeterminate Lesions or Choroidal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aura Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aura Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational research study is to follow participants who have been&#xD;
      treated with either AU-011 or observation and/or received standard of care therapy while&#xD;
      participating in a previous Aura Biosciences clinical research study to assess the long-term&#xD;
      safety and effectiveness of AU-011 and standard of care therapy. This study will collect&#xD;
      information from procedures conducted as part of routine follow-up eye care and cancer care.&#xD;
      Additionally, the registry will collect all adverse events, information about pregnancy and&#xD;
      symptomatic overdose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center long-term observational Registry of patients with Primary&#xD;
      Indeterminate Lesions or Choroidal Melanoma.&#xD;
&#xD;
      The Registry will initially be open to patients who have previously participated in an Aura&#xD;
      Biosciences sponsored clinical trial for their primary Choroidal Melanoma or Indeterminate&#xD;
      Lesions.&#xD;
&#xD;
      All patients will be followed for a minimum of 5 years (including time enrolled in an Aura&#xD;
      sponsored clinical trial), until withdrawal of consent, or until death whichever comes first.&#xD;
&#xD;
      No interventions will be required as part of the Registry. Data collection will be based on&#xD;
      IL or CM information anticipated to be available based on the standard of care for patients&#xD;
      with CM or IL; these patients are routinely followed at 6-month intervals by their treating&#xD;
      physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2019</start_date>
  <completion_date type="Anticipated">December 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Related Adverse Events</measure>
    <time_frame>5 years</time_frame>
    <description>Treatment related adverse events will be assessed and graded using CTCAE v5.0. The number and percentage of patients with treatment related adverse events will be summarized.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Choroidal Melanoma</condition>
  <condition>Indeterminate Lesions of Eye</condition>
  <arm_group>
    <arm_group_label>Patients previously participated in an Aura Biosciences study</arm_group_label>
    <description>Patients with Choroidal Melanoma or Indeterminate Lesions.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary Choroidal Melanoma and Indeterminate Lesions who participated in&#xD;
        previous Aura Biosciences sponsored clinical trial.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have been clinically diagnosed with primary IL or CM at the time of entry to a&#xD;
             previous Aura Biosciences sponsored clinical trial.&#xD;
&#xD;
          -  Have received AU-011 or assigned to an observation cohort in a previous Aura sponsored&#xD;
             clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhijit Narvekar, MBBS MS DPM</last_name>
    <role>Study Director</role>
    <affiliation>Aura Biosciences Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rochelle Summerfelt, MS</last_name>
    <phone>(773) 855-8157</phone>
    <email>rsummerfelt@aurabiosciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abhijit Narvekar, MBBS MS DPM</last_name>
    <phone>617-250-7255</phone>
    <email>anarvekar@aurabiosciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Retina Associates SW, P.C.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenifer Martin</last_name>
      <phone>520-617-2805</phone>
      <email>jmartin@retinatucson.com</email>
    </contact>
    <contact_backup>
      <last_name>Amy Winkel-Merz</last_name>
      <phone>520-886-2597</phone>
      <email>amerz@retinatucson.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cameron Javid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Jules Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Chavez</last_name>
      <phone>310-794-5596</phone>
      <email>frankchavez@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Andrade</last_name>
      <phone>310-267-5278</phone>
      <email>sdandrade@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tara McCannel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariana Nunez</last_name>
      <phone>650-497-7846</phone>
      <email>mnunez1@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Prithi Mruthyunjaya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Nickerman</last_name>
      <phone>916-453-5452</phone>
      <email>nickermane@retinalmd.com</email>
    </contact>
    <investigator>
      <last_name>Tony Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustafa Hasmi</last_name>
      <phone>617-573-3066</phone>
      <email>mustafa_hashmi@meei.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Monica Oxenreiter</last_name>
      <phone>617-573-4382</phone>
      <email>monica_oxenreiter@meei.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ivana Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>W. K. Kellogg Eye Center, University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Campbell</last_name>
      <phone>734-936-0138</phone>
      <email>pamtitus@@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Hakan Demirci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Retinal Consultants, PC</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kendra Mellert</last_name>
      <phone>248-288-9132</phone>
      <phone_ext>1315</phone_ext>
      <email>kmellert@arcpc.net</email>
    </contact>
    <investigator>
      <last_name>Antonio Capone Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andi Gilchrist, BS CMSS</last_name>
      <phone>612-746-3880</phone>
      <email>agilchrist@retinadocs.com</email>
    </contact>
    <contact_backup>
      <last_name>Celeste Moreno</last_name>
      <phone>612-746-3880</phone>
      <email>cmoreno@retinadocs.com</email>
    </contact_backup>
    <investigator>
      <last_name>Abdhish R Bhavsar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Swathi Balaji</last_name>
      <phone>212-304-5548</phone>
      <email>sb4461@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Magana</last_name>
      <phone>212-304-5545</phone>
      <email>wm2443@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Brian Marr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ann Lundquist</last_name>
      <phone>503-494-6364</phone>
      <email>lundquia@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Alison Skalet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Cotelesa</last_name>
      <phone>215-928-3105</phone>
      <email>lisac@shields.md</email>
    </contact>
    <investigator>
      <last_name>Carol Shields, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Carolina, PA</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Frazier</last_name>
      <phone>864-233-5722</phone>
      <phone_ext>1107</phone_ext>
      <email>lfrazier@retina-consultants.com</email>
    </contact>
    <investigator>
      <last_name>Chris Bergstrom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Thomas Health / Tennessee Retina, PC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Walden</last_name>
      <phone>615-345-8912</phone>
      <email>lwalden@tnretina.com</email>
    </contact>
    <investigator>
      <last_name>David Reichstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Arceneaux</last_name>
      <phone>214-692-6885</phone>
      <phone_ext>2</phone_ext>
      <email>sarceneaux@texasretina.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Fuller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsey L Moore, CMSS</last_name>
      <phone>713-394-7575</phone>
      <email>chelsey.moore@houstonretina.com</email>
    </contact>
    <investigator>
      <last_name>Amy C Schefler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ocularmelanoma.org/</url>
    <description>Ocular Melanoma</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Choroidal Melanoma</keyword>
  <keyword>Indeterminate Lesions of Eye</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

